Buyout potential on this one.
AUPH spent the summer as a bummer for all who bought the secondary at $15, but fall conferences ( OPCO on SEPT 23) will get the bystanders in this jewel which should eventually be bought out.
A close today anywhere near 14.75 would virtually guarantee it. Target 18.40
AUPH is sitting on fib support here. Great spot to buy. Expecting this one to double.
Looks like a perfect ABCDE correction is about to breakout. Short term targets as per chart.
Hello, What is AUPH? Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. News Last week Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that it completed a regulatory submission to the FDA seeking approval for its drug, voclosporin. If successful,...
If pattern breaks down short term run looks good to $18.30
NASDAQ:AUPH will stabilize after the stock dilution and continue to its true value in the teens. Buy on the dip. ir.auriniapharma.com ir.auriniapharma.com
www.fool.com Expecting this stock to pull back but the motley fool gives long advice.
AUPH to hold for greater gains in the near future. See comments on chart for more information. No BUY or SELL targets.
Entry level $8.00 = Target price $9.75 = Stop loss $7.50 Possible long term breakout in the stock which has made a nice recovery on the back of earnings surprise. It's possible it may consolidate for a few days on the market weakness. Average analysts price target $13 | BUY rating High 14% short interest Company profile Aurinia Pharmaceuticals, Inc. operates as...
Phase 3 Trial News about to be released within 2 weeks, most likely first week of December
- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001) - AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017 ir.auriniapharma.com seekingalpha.com
ir.auriniapharma.com